Jun 19th 2012 - Edison Investment Research today published a report on MediGene entitled "Refuelling RhuDex". In summary, the report says:
We raise our valuation of Medigene by €5m to €81m following the recent monetisation of its remaining interest in non-core asset Eligard for €14.1m, which we estimate will extend its cash runway by more than 12 months to beyond 2014. Importantly, Medigene now has the flexibility and resources required to implement a significant clinical programme for RhuDex, a disease-modifying anti-rheumatic agent increasingly important to the investment case.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »